Fagron N.V.
Supplies compounding ingredients and solutions for personalized medicine to healthcare professionals.
FAGR | BR
Overview
Corporate Details
- ISIN(s):
- BE0003874915
- LEI:
- 549300TRKRUFK2RRG779
- Country:
- Belgium
- Address:
- Venecoweg 20A, 9810 Nazareth
- Website:
- https://fagron.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Fagron N.V. is a global pharmaceutical company that specializes in pharmaceutical compounding to advance personalized medicine. The company focuses on optimizing and innovating customized pharmaceutical care for hospitals, pharmacies, clinics, and prescribers. Fagron develops and supplies a wide range of products, including pharmaceutical raw materials, active pharmaceutical ingredients (APIs), excipients, and innovative compounding vehicles such as Pentravan® (a transdermal base) and SyrSpend® (oral suspending vehicles). By providing these solutions, Fagron empowers healthcare professionals to prepare sterile and non-sterile medications tailored to the unique needs of individual patients, thereby widening the therapeutic scope of prescribers worldwide.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Fagron N.V. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-31 08:22 |
Earnings Release
Fagron delivers strong performance with 11% topline growth and 12% increase in …
|
English | 209.5 KB | |
| 2025-07-31 08:22 |
Earnings Release
Fagron delivers strong performance with 11% topline growth and 12% increase in …
|
English | 987.2 KB | |
| 2025-07-31 08:21 |
Earnings Release
Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van …
|
Dutch | 205.8 KB | |
| 2025-07-31 08:21 |
Earnings Release
Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van …
|
Dutch | 993.4 KB | |
| 2025-07-31 07:00 |
Interim Report
Fagron - IFS 30-07-2025 EN.pdf
|
English | 1.6 MB | |
| 2025-07-31 07:00 |
Interim Report
Fagron - IFS 30-07-2025 NL.pdf
|
Dutch | 1.6 MB | |
| 2025-07-31 07:00 |
Earnings Release
Fagron - H1 2025 PR EN.pdf
|
English | 987.2 KB | |
| 2025-07-31 07:00 |
Earnings Release
Fagron - H1 2025 PR NL.pdf
|
Dutch | 993.4 KB | |
| 2025-07-31 07:00 |
Interim Report
Fagron - IFS 30-07-2025 EN.pdf
|
English | 1.6 MB | |
| 2025-07-31 07:00 |
Interim Report
Fagron - IFS 30-07-2025 NL.pdf
|
Dutch | 1.6 MB | |
| 2025-07-31 07:00 |
Earnings Release
Fagron - H1 2025 PR EN.pdf
|
English | 987.2 KB | |
| 2025-07-31 07:00 |
Earnings Release
Fagron - H1 2025 PR NL.pdf
|
Dutch | 993.4 KB | |
| 2025-07-21 07:39 |
Major Shareholding Notification
Disclosure of notification received from Alychlo
|
Dutch | 479.4 KB | |
| 2025-07-21 07:39 |
Major Shareholding Notification
Disclosure of notification received from Alychlo
|
English | 489.9 KB | |
| 2025-07-18 18:00 |
Major Shareholding Notification
250718_Fagron transparency Alychlo_PR_ENG.pdf
|
English | 489.9 KB |
Automate Your Workflow. Get a real-time feed of all Fagron N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Fagron N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-05-23 | Pulido Andrew | Executive member | Sell | 85,000 | 1,803,351.50 EUR |
| 2025-05-22 | Pulido Andrew | Executive member | Buy | 85,000 | 1,617,550.00 EUR |
| 2025-05-02 | De Jong Cornelia Neeltje | Board | Sell | 12,689 | 263,834.55 EUR |
| 2025-04-30 | De Jong Cornelia Neeltje | Board | Sell | 229 | 4,660.15 EUR |
| 2025-04-29 | De Jong Cornelia Neeltje | Board | Sell | 10,000 | 201,500.00 EUR |
| 2025-03-28 | J. Verlinden | Other | Buy | 24,551 | 453,702.48 EUR |
| 2025-03-28 | J. Verlinden | Other | Sell | 17,930 | 344,047.56 EUR |
| 2025-03-27 | Padilla Rafael | Board | Buy | 78,469 | 1,450,107.12 EUR |
| 2025-03-27 | De Jong Cornelia Neeltje | Board | Buy | 45,418 | 839,324.64 EUR |
| 2025-02-21 | Bakker Vera | Executive member | Buy | 773 | 15,000.00 EUR |
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
